We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

AstraZeneca plc (AZN) Ordinary US$0.25

Sell:10,688.00p Buy:10,690.00p 0 Change: No change
FTSE 100:0.26%
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:10,688.00p
Buy:10,690.00p
Change: No change
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:10,688.00p
Buy:10,690.00p
Change: No change
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

Contact details

Address:
1 Francis Crick Avenue
CAMBRIDGE
CB2 0AA
United Kingdom
Telephone:
+44 (020) 73045000
Website:
https://www.astrazeneca.com/

Important dates

Future events
Quarterly results 25 April 2024 25/04/24
AGM 11 April 2024 11/04/24
Past events
Interim dividend payment date 25 March 2024 25/03/24
Interim ex-dividend date 22 February 2024 22/02/24
Annual report 20 February 2024 20/02/24
Final results 08 February 2024 08/02/24
Quarter 4 results 08 February 2024 08/02/24
Quarter 3 results 09 November 2023 09/11/23
Interim dividend payment date 11 September 2023 11/09/23
Interim ex-dividend date 10 August 2023 10/08/23
Quarter 2 results 28 July 2023 28/07/23
Interim results 28 July 2023 28/07/23
AGM 27 April 2023 27/04/23
Quarterly results 27 April 2023 27/04/23

General stock information

EPIC:
AZN
ISIN:
GB0009895292
Market cap:
£165.53 billion
Shares in issue:
1.55 billion
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 100,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • Pascal Soriot
    Chief Executive Officer, Executive Director
  • Aradhana Sarin
    Chief Financial Officer, Executive Director
  • Marc Dunoyer
    Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
  • Jeffrey Pott
    Chief Human Resource Officer, Chief Compliance Officer, General Counsel
  • Sharon Barr
    Executive Vice President - BioPharmaceuticals R&D
  • Pam Cheng
    Executive Vice President - Global Operations, Information Technology and Chief Sustainability Officer
  • Ruud Dobber
    Executive Vice President - BioPharmaceuticals Business Unit
  • David Fredrickson
    Executive Vice President - Oncology Business Unit
  • Susan Galbraith
    Executive Vice President - Oncology and Research and Development
  • Iskra Reic
    Executive Vice President - Vaccines and Immune Therapies

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.